HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH)(“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Tara Sadeghi has joined the company as Director of Clinical Operations. Reporting to Dr. Ulrich Mueller, Chief Operating Officer, Ms. Sadeghi will be responsible for all clinical activities surrounding the Company’s drug development programs.
Help employers find you! Check out all the jobs and post your resume.
